share_log

Insiders Own 31% of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares but Retail Investors Control 44% of the Company

Insiders Own 31% of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares but Retail Investors Control 44% of the Company

业内人士拥有沈阳兴奇药业有限公司 31% 的股份, Ltd.(深交所代码:300573)持有公司 44% 的股份,但散户投资者控制着该公司 44% 的股份
Simply Wall St ·  2023/11/24 18:06

Key Insights

关键见解

  • Significant control over Shenyang Xingqi PharmaceuticalLtd by retail investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 14 investors have a majority stake in the company with 51% ownership
  • 31% of Shenyang Xingqi PharmaceuticalLtd is held by insiders
  • 散户投资者对沈阳兴奇制药有限公司的重大控制意味着公众有更大的权力影响管理和治理相关决策
  • 共有14名投资者拥有该公司的多数股权,拥有51%的所有权
  • 沈阳兴奇药业有限公司31%的股份由内部人士持有

A look at the shareholders of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

看看沈阳兴奇药业有限公司的股东,Ltd.(深圳证券交易所代码:300573)可以告诉我们哪个集团最强大。而占有最大份额的群体是拥有44%所有权的散户投资者。换句话说,该集团面临着最大的上行潜力(或下行风险)。

Meanwhile, individual insiders make up 31% of the company's shareholders. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones.

同时,个人内部人士占公司股东的31%。机构通常会持有大型公司的股票,我们预计内部人士将拥有相当一部分小型公司的股票。

Let's delve deeper into each type of owner of Shenyang Xingqi PharmaceuticalLtd, beginning with the chart below.

让我们从下表开始,更深入地研究沈阳兴奇制药有限公司的每种类型的所有者。

Check out our latest analysis for Shenyang Xingqi PharmaceuticalLtd

查看我们对沈阳兴奇药业有限公司的最新分析

ownership-breakdown
SZSE:300573 Ownership Breakdown November 24th 2023
深交所:300573 所有权明细 2023 年 11 月 24 日

What Does The Institutional Ownership Tell Us About Shenyang Xingqi PharmaceuticalLtd?

机构所有权告诉我们关于沈阳兴奇药业有限公司的什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

We can see that Shenyang Xingqi PharmaceuticalLtd does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Shenyang Xingqi PharmaceuticalLtd, (below). Of course, keep in mind that there are other factors to consider, too.

我们可以看到,沈阳兴奇制药有限公司确实有机构投资者;他们持有公司很大一部分股票。这可能表明该公司在投资界具有一定程度的信誉。但是,最好谨慎行事,不要依赖机构投资者提供的假定验证。有时候他们也会弄错。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,值得一看沈阳兴奇制药有限公司过去的收益轨迹(见下图)。当然,请记住,还有其他因素需要考虑。

earnings-and-revenue-growth
SZSE:300573 Earnings and Revenue Growth November 24th 2023
深交所:300573 收益和收入增长 2023年11月24日

We note that hedge funds don't have a meaningful investment in Shenyang Xingqi PharmaceuticalLtd. Jidong Liu is currently the largest shareholder, with 29% of shares outstanding. With 4.8% and 3.4% of the shares outstanding respectively, National Council for Social Security Fund and Fullgoal Fund Management Co. Ltd. are the second and third largest shareholders. In addition, we found that E. Gao, the CEO has 1.2% of the shares allocated to their name.

我们注意到,对冲基金没有对沈阳兴奇药业有限公司进行有意义的投资。刘继东目前是最大股东,持有29%的已发行股份。全国社会保障基金理事会和Fullgoal基金管理公司分别占已发行股份的4.8%和3.4%Ltd. 是第二和第三大股东。此外,我们发现,首席执行官高英拥有1.2%的股份分配给他们。

After doing some more digging, we found that the top 14 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

经过进一步的挖掘,我们发现排名前14位的公司合并所有权为51%,这表明没有一个股东对公司拥有重要的控制权。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。分析师对该股的报道很少,但报道不多。因此,它还有获得更多报道的余地。

Insider Ownership Of Shenyang Xingqi PharmaceuticalLtd

沈阳兴奇药业有限公司的内幕所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。

Our information suggests that insiders maintain a significant holding in Shenyang Xingqi Pharmaceutical Co.,Ltd.. It is very interesting to see that insiders have a meaningful CN¥5.6b stake in this CN¥18b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

我们的信息表明,内部人士仍持有沈阳兴奇药业有限公司的大量股份。,有限公司。看到内部人士在这项180亿元人民币的业务中拥有56亿元人民币的大量股份,这非常有趣。很高兴看到这样的投资水平。你可以在这里查看这些内部人士最近是否在买入。

General Public Ownership

一般公有制

With a 44% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shenyang Xingqi PharmaceuticalLtd. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

沈阳兴齐药业有限公司拥有44%的所有权,公众对沈阳兴奇药业有限公司有一定程度的影响力,主要由个人投资者组成。尽管这个群体不一定能做主,但它肯定会对公司的运作方式产生真正的影响。

Next Steps:

后续步骤:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Shenyang Xingqi PharmaceuticalLtd (including 1 which is significant) .

尽管值得考虑拥有一家公司的不同群体,但还有其他因素更为重要。为此,你应该了解我们在沈阳兴奇制药有限公司发现的两个警告信号(包括一个重要的警告)。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一样,你可能需要考虑这家公司是会成长还是会萎缩。幸运的是,您可以查看这份免费报告,其中显示了分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发